Nonpartisan political forums. Political blogs. International news.

(1) the test is one-fifth the size of a statistically accurate study,

(2) is, at 4 weeks, too short term to see its effects on diabetes, cholesterol levels or, for that matter, heart problems (like Biaxin),

(3) is the first of its kind and has not been corroborated, and

(4) the initial test results that Lilly published about Zyprexa were just as rosy as this one."

More,interesting comments at this discussion thread

http://www.topix.net/forum/source/indianapolis-star/TH5QQNTOV4FIT78IR

 * * * * *

From Lilly's own PR news wire:

http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=262455

"About LY2140023

LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia.

 Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.

Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023."

* * * * *

Daniel Haszard http://www.zyprexa-victims.com

http://www.google.com/search?hl=en&q=Daniel+Haszard+Zyprexa+&btnG=Google+Search

I have over 50,000 pages up!